Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | KLK5 | Q9Y337 | 7/20 | 0.42 |
| ▸ | KLK7 | P49862 | 7/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7498881 | 0.89 | PDE4B (0.59) | PDE4BL3MBTL1KMT2ACTSKCTSL | |
| SCHEMBL30060223 | 0.89 | PDE4B (0.59) | PDE4BL3MBTL1KMT2ACTSKCTSL | |
| SCHEMBL1360264 | 0.89 | PDE4B (0.56) | PDE4BL3MBTL1KMT2ACTSLSYK | |
| SCHEMBL1360262 | 0.89 | PDE4B (0.56) | PDE4BL3MBTL1KMT2ACTSLSYK | |
| SCHEMBL30061382 | 0.86 | PDE4B (0.54) | PDE4BL3MBTL1KMT2ACTSKCTSL | |
| SCHEMBL20722589 | 0.86 | PDE4B (0.54) | PDE4BL3MBTL1KMT2ACTSKCTSL | |
| SCHEMBL12426645 | 0.86 | PDE4B (0.56) | PDE4BL3MBTL1KMT2ACTSKCTSL | |
| SCHEMBL9051439 | 0.85 | PDE4B (0.59) | PDE4BL3MBTL1KMT2ACTSKCTSL | |
| SCHEMBL24509184 | 0.85 | PDE4B (0.59) | PDE4BL3MBTL1KMT2ACTSKCTSL | |
| SCHEMBL9053027 | 0.85 | PDE4B (0.59) | PDE4BL3MBTL1KMT2ACTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| CN-112867712-B | Carboxamide as ubiquitin-specific protease inhibitor | 瓦洛早期发现股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO EARLY DISCOVERY, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524966-B1 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | PDE4B 3612/4885L3MBTL1 1885/4885KMT2A 339/4885 |
| US-20210323975-A1 | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | USP28, USP25, USP24 | PDE4B 3612/4885L3MBTL1 1885/4885KMT2A 339/4885 |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | PDE4B 3612/4885L3MBTL1 1885/4885KMT2A 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.